日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer

18F-FDG PET在肺癌个体化放疗或放化疗中的应用潜力

Choi, Noah C; Chun, Tristen T; Niemierko, Andrzej; Ancukiewicz, Marek; Fidias, Panos M; Kradin, Richard L; Mathisen, Douglas J; Lynch, Thomas J; Fischman, Alan J

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer

厄洛替尼联合羟氯喹治疗晚期非小细胞肺癌的I期研究

Goldberg, Sarah B; Supko, Jeffrey G; Neal, Joel W; Muzikansky, Alona; Digumarthy, Subba; Fidias, Panos; Temel, Jennifer S; Heist, Rebecca S; Shaw, Alice T; McCarthy, Patricia O; Lynch, Thomas J; Sharma, Sreenath; Settleman, Jeffrey E; Sequist, Lecia V

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

肺癌获得对EGFR抑制剂耐药性的基因型和组织学演变

Sequist, Lecia V; Waltman, Belinda A; Dias-Santagata, Dora; Digumarthy, Subba; Turke, Alexa B; Fidias, Panos; Bergethon, Kristin; Shaw, Alice T; Gettinger, Scott; Cosper, Arjola K; Akhavanfard, Sara; Heist, Rebecca S; Temel, Jennifer; Christensen, James G; Wain, John C; Lynch, Thomas J; Vernovsky, Kathy; Mark, Eugene J; Lanuti, Michael; Iafrate, A John; Mino-Kenudson, Mari; Engelman, Jeffrey A

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

EGF 受体的不可逆抑制剂可以克服对吉非替尼的获得性耐药性

Kwak Eunice L, Sordella Raffaella, Bell Daphne W, Godin-Heymann Nadia, Okimoto Ross A, Brannigan Brian W, Harris Patricia L, Driscoll David R, Fidias Panos, Lynch Thomas J, Rabindran Sridhar K, McGinnis John P, Wissner Allan, Sharma Sreenath V, Isselbacher Kurt J, Settleman Jeffrey, Haber Daniel A